The present study has established the ZHX2-LPL axis that maintains hepatocytic lipid homeostasis, hampers NAFLD development and NAFLD–HCC progression, and suppresses HCC tumor growth. This evidence concerns the gene ZHX2 and metabolic dysfunction-associated steatotic liver disease.